stevebarrett

Researchers evaluated the association between osteoporosis and vertebral fragility fractures with cardiovascular calcification in patients with chronic obstructive pulmonary disease.

Acromegaly is associated with an increased risk for mortality from vascular and respiratory disease, but not malignant disease.

In patients admitted to the hospital with COVID-19 in New York City, critical illness is common and associated with high frequency of invasive mechanical ventilation.

SAN FRANCISCO — Empagliflozin has a consistent cardioprotective effect in patients with type 2 diabetes (T2D) and cardiovascular disease (CVD), regardless of the number of CV risk factors that are controlled, according to research presented at the 79th Scientific Sessions of the American Diabetes Association, held June 7 to 11, 2019, in San Francisco. Researchers…

The United States Preventive Services Task Force does not recommend screening with resting or exercise electrocardiography in asymptomatic individuals at low risk for cardiovascular disease events.

Women with atrial fibrillation and diabetes had a higher risk for mortality and cardiovascular complications compared with men.

Patients treated with zoledronic acid vs oral bisphosphonates had higher risk for heart failure and arrhythmias.

Compared with insulin glargine, insulin degludec significantly reduced rates of hypoglycemia in patients with either type 1 or type 2 diabetes.

Patients with type 2 diabetes who were initiated on insulin therapy increased their sitting time and decreased their low-intensity physical activity.

N-terminal pro-B-type natriuretic peptide showed the strongest association with heart failure in patients with type 2 diabetes.

The least common condition, systemic lupus erythematosus, was associated with the highest association of experiencing multiple cardiometabolic events.

Two-hour postload glucose better predicted cardiovascular events compared with fasting plasma glucose and HbA1c.

Patients with diabetes had higher hospital readmission rates compared with patients who did not have diabetes.

Over 200 patients participated in the study of a novel immunoassay used to distinguish hypertension from hyperaldosteronism.

Two studies examined the effects of naltrexone/bupropion on weight loss, glycemic parameters, and cardiovascular risks in patients with type 2 diabetes.

Patients with type 2 diabetes taking statins after insulin initiation had better glycemic control, but their risk for mortality was higher compared with patients who did not take statins.

Flow mediated dilation changes improved in patients who received dapagliflozin.

Sitagliptin improved glucose excursion and lowered triglyceride levels in men with prediabetes who were also overweight.

Patients with cardiovascular disease and both type 2 diabetes and chronic kidney disease had the highest risk for mortality.

First look at research to be presented at ADA 2017.

Patients with type 1 diabetes had higher mortality rates when admitted for acute myocardial infarction compared with patients with type 2 diabetes.

After 24 months, bone mineral density was statistically different from baseline.

First look at research being presented at AACE 2017.

Women with preeclampsia and pregnancy-associated stroke were more likely to have preexisting hypertension than controls.

Neither DXA-visceral adipose tissue nor android-gynoid fat mass ratios were associated with atherosclerotic cardiovascular disease events.

This week, find out which dietary changes may affect diabetes, learn about a genetic risk factor for hip fracture, and how older mothers are faring compared with their younger counterparts.

Patients with vitamin D deficiency had significantly higher total cholesterol, non-HDL-C, triglycerides, and lipoprotein ratios overall.

Higher levels of free T4 were associated with atrial fibrillation, but TSH and total T3 were not.

Pancreatic polypeptide significantly correlated with Framingham 10-year risk for coronary artery disease.

Both mean body weight and body mass index were reduced with empagliflozin in patients with diabetes following cardiac transplant.